Trachelogenin

Research use only, not for human use.

Trachelogenin, an HCV entry inhibitor, has antiproliferative effects, and its mechanism is related to affecting the phosphorylation of key proteins in the β-Catenin signaling pathway, such as β-Catenin, c-Myc, and GSK3, in a concentration-dependent manner.

Trachelogenin, an HCV entry inhibitor, has antiproliferative effects, and its mechanism is related to affecting the phosphorylation of key proteins in the β-Catenin signaling pathway, such as β-Catenin, c-Myc, and GSK3, in a concentration-dependent manner.Trachelogenin exhibits antiviral, anti-inflammatory, and analgesic activities, with IC50 values of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin has antiviral, anti-inflammatory and analgesic activities, with IC50s of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively.Trachelogenin is a compound derived from Combretum fruticosum.

Others

Other Targets

——

——

——

34209-69-3

388.2

C21H24O7

>98% (HPLC)

——

——

(-20℃)

With Ice Pack

≥ 2 years